Merrion Pharma Pulls IPO

Merrion Pharmaceuticals Ltd., a Dublin, Ireland-based developer of oral-dosage forms of drugs with poor bioavailability, has withdrawn its IPO registration. The company had planned to price four million American depository shares at a revised range of between $6 and $7 per share. The original range had been between $10 and $12 per share.


Merrion had planned to trade on both the Nasdaq under ticker symbol MERR, with Punk, Ziegel & Co. serving as lead underwriter. Shareholders include Growcorp Ltd. and Elan Corp.